FDMT vs SRPT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SRPT Captures Institutional Edge (3โ1 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Sarepta Therapeutics,, Inc. Common Stock (SRPT) driven by superior Valuation, Growth & Margin, Options & Structure while FDMT counters with relative strength in Momentum & Technical. Fundamentally, FDMT trades at N/M Forward P/E with -222.7% operating margin (+4505.6% YoY revenue) versus SRPT at 10.8x Forward P/E and -0.4% operating margin (-4.5% YoY). In options structure, FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro) against SRPT sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | FDMT Revenue | SRPT Revenue | FDMT Op. Margin | SRPT Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $300M | N/A | -114.1% | SRPT |
| FY2019 | $10M | $380M | -729.4% | -185.3% | SRPT |
| FY2020 | $10M | $460M | -424.0% | -123.8% | SRPT |
| FY2021 | $20M | $610M | -395.5% | -75.1% | SRPT |
| FY2022 | $0M | $840M | -3516.5% | -63.5% | SRPT |
| FY2023 | $20M | $1.14B | -544.6% | -23.4% | SRPT |
| FY2024 | $0M | $1.79B | -507678.4% | 12.2% | SRPT |
| FY2025 | $90M | $1.86B | -187.2% | -37.5% | SRPT |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | FDMT | SRPT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $669.3M | $1.7B | Larger Scale | SRPT |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | 10.8x | Lower Multiple | SRPT |
| Revenue Growth (YoY) Growth | +4505.6% | -4.5% | Higher Growth | FDMT |
| Operating Margin (TTM) Profitability | -222.7% | -0.4% | Higher Margin | SRPT |
| Net Profit Margin Profitability | -208.6% | -5.9% | Higher Margin | SRPT |
| Return on Equity (ROE) Capital Efficiency | -56.7% | -8.1% | Higher ROE | SRPT |
| 52-Week Range Position Momentum | 47% ($7โ$17) | 5% ($15โ$25) | Stronger Trend | FDMT |
| Beta / 30D Volatility Risk Regime | 1.89ฮฒ ยท 90% Vol | 1.47ฮฒ ยท 58% Vol | Lower Realized Risk | SRPT |
| Unified Institutional Score Composite Signal | 42.1 / 100 (HOLD) | 36.8 / 100 (SELL) | Higher Composite | FDMT |